Orphan Drug Designation Granted to TST1001 for Gastric Cancer

The FDA has recently granted Orphan Drug designation to TST1001, Transcenta Holding Limited's monoclonal antibody for gastric cancer/gastroesophageal junction (GC/GEJ). Prior research has demonstrated TST1001's anti-tumor activity, and ongoing research…

Continue Reading Orphan Drug Designation Granted to TST1001 for Gastric Cancer